History
We have grown into a trusted name in the pharmaceutical industry, dedicated to enhancing lives through advanced medical solutions.
A Legacy of Excellence in Pharmaceuticals
Ciba Pharmaceuticals was founded in 2016 by a team of visionary businessmans who aimed to transform the pharmaceutical industry. The founders, who had backgrounds in the same industry since 1990,, and were united by a shared belief: to make high-quality, affordable medications accessible to all. The company was established in Karachi, Pakistan with a state-of-the-art manufacturing plant designed to meet international pharmaceutical standards.
In its first year, Ciba Pharmaceutical focused on creating a diverse range of products, starting with treatments for common ailments such as digestive disorders, pain management, and respiratory conditions. The company introduced five major Sections: sachets, tablets, capsules, dry suspensions, and creams/ointments. These early products were aimed at addressing both over-the-counter and prescription-based needs, offering versatile treatment options across different patient groups.
Ciba’s early success was marked by the rapid adoption of its products across key global markets. By 2018, the company had launched its flagship product line, which quickly gained traction due to its ease of use and affordability. The sachets, specifically designed for quick dissolving and immediate relief, were widely recognized in markets requiring accessible treatments for ailments such as dehydration, flu symptoms, and minor gastrointestinal issues.
The tablet and capsule offerings were enhanced with advanced drug-delivery systems, ensuring higher bioavailability and faster action. The company’s dry suspension line, tailored for children and patients who had difficulty swallowing pills, became particularly popular in pediatrics.
As Ciba Pharma grew, so did its commitment to innovation. In 2020, the company established an in-house research and development (R&D) division aimed at improving drug formulations and exploring new therapeutic areas. The team focused on creating treatments for chronic conditions like diabetes, hypertension, and arthritis, while also investigating more specialized treatments for rare diseases.
Ciba also began to focus on sustainable practices, ensuring that its manufacturing processes were environmentally friendly and that the packaging of its products was made from recyclable materials. The introduction of advanced topical formulations, including high-quality creams and ointments, helped the company expand into dermatology, with products addressing everything from acne to eczema.
Ciba continues with a growing portfolio of products, including advanced drug formulations in its tablets, capsules, and topical treatments, the company has become a trusted name in patient care. Ciba’s continued dedication to R&D has led to the development of groundbreaking treatments for chronic conditions like diabetes, heart disease, and neurological disorders.
The company has also embraced digital health solutions, offering telemedicine platforms and patient support programs to further enhance the patient experience and ensure that treatment adherence is optimized. In addition, Ciba is exploring new areas of biotechnology, with an eye on personalized medicine and cutting-edge therapies.
In addition, The company’s toll-manufactured products, including the Vitamin D3 drops, Cefixime injections, and Ceftriaxone injections, were produced under strict quality control guidelines in partnership with leading manufacturing facilities. Ciba Pharma’s production processes followed stringent Good Manufacturing Practices (GMP) to ensure that these critical products met the highest standards of safety and effectiveness. This expansion was complemented by a strategic move into toll manufacturing, which enabled PharmTech to offer toll-manufacturing services for various products, including sachets and creams/ointments.
International Markets
Simultaneously, Ciba Pharma expanded its international footprint by exporting its products to Afghanistan and Yemen. These two countries became key markets for Ciba Pharma’s sachets, dry suspensions, and topical treatments. In Afghanistan, Ciba’s sachets for hydration, gastrointestinal issues, and flu relief were in high demand, while in Yemen, its antibiotics and creams helped meet the country’s growing healthcare needs.
As Ciba Pharma, took significant steps to focus on expanding its presence in international markets. The company recognized that access to affordable, high-quality healthcare products was a major challenge in developing countries, especially those affected by ongoing conflicts or limited healthcare infrastructure.
